Cancer Focus Fund

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Starget Pharma is a biotechnology company focused on developing advanced targeted radiopharmaceutical technologies for the treatment of solid tumors. The company specializes in creating novel molecules that serve as vectors to selectively deliver radioisotopes directly to cancerous tissues. By addressing unmet medical needs in cancer treatment, Starget Pharma aims to enhance the efficacy of therapeutic interventions, enabling healthcare professionals to provide more effective solutions for patients battling cancer. Through its innovative research pipeline, the company strives to improve diagnostic and treatment options in the oncology field.

Eisbach Bio is a biotechnology company established in 2019 and located in Martinsried, Bavaria. The company specializes in developing innovative drugs that target molecular vulnerabilities in cancer genomes, focusing particularly on chromatin regulatory mechanisms. By utilizing screening and cellular platforms, Eisbach Bio aims to create first-in-class inhibitors that directly address the key vulnerabilities present in genetically defined tumors. This approach enables healthcare professionals to tackle unmet clinical needs in cancer treatment and supports the advancement of new therapies aimed at stopping tumor growth.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

ImmunoGenesis is a biotechnology company focused on developing innovative immune therapies aimed at treating tumors that exhibit low levels of activated T cells or possess other mechanisms of immune resistance. The company specializes in creating immuno-oncology therapeutics designed to address the challenges of immunologically cold cancers, including prostate, colorectal, and pancreatic cancer. By targeting critical mechanisms of immune resistance, ImmunoGenesis aims to facilitate effective immune responses in these difficult-to-treat cancer types, ultimately providing healthcare professionals with access to advanced therapies that enhance treatment options for patients.

Nectin Therapeutics Ltd. is a biotechnology company founded in 2017 and based in Jerusalem, Israel. The company specializes in the development of novel monoclonal antibodies that target members of the Nectin family of receptors and ligands, which play significant roles in immune checkpoint mechanisms relevant to cancer immunotherapy. Nectin Therapeutics focuses on creating therapies for both solid and hematological malignancies by designing antibodies that can bypass the inhibitory pathways used by tumors, thereby enhancing the ability of immune cells to effectively eliminate cancer cells. Through its innovative approach, the company aims to improve patient outcomes in the fight against cancer.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.